Compare

Dermata Therapeutics, Inc. vs Processa Pharmaceuticals, Inc. vs Acurx Pharmaceuticals, Inc. vs GT Biopharma, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Dermata Therapeutics, Inc. DRMA	Processa Pharmaceuticals, Inc. PCSA	Acurx Pharmaceuticals, Inc. ACXP	GT Biopharma, Inc. GTBP
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	n/a	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	-$7.56M	-$13.56M	-$7.97M	-$28.35M
EPS (Diluted)	-$8.16	-$10.36	-$5.32	-$6.68
Operating cash flow	-$7.76M	-$11.39M	-$6.79M	-$12.91M
Free cash flow	n/a	n/a	n/a	n/a
Cash & equivalents	$7.52M	$5.54M	n/a	$6.81M
Total assets	$7.86M	$7.81M	$7.69M	$8.11M
Total liabilities	$1.64M	$2.24M	$2.42M	n/a
Shareholders' equity	$6.22M	$5.58M	$5.27M	$5.79M
Return on year-end equity	-121.5%	-243.2%	-151.2%	-490.0%
Shares outstanding	2.66M	2.57M	2.35M	25.53M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Dermata Therapeutics, Inc.	Processa Pharmaceuticals, Inc.	Acurx Pharmaceuticals, Inc.	GT Biopharma, Inc.
Latest	n/a	$0 Ended 2022-12-31	n/a	$0 Ended 2020-12-31
1 year earlier	n/a	$0 Ended 2021-12-31	n/a	$0 Ended 2019-12-31
2 years earlier	n/a	n/a	n/a	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a